SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival
2017
Expression of the solute carrier (SLC) transporter SLC22A3 gene
is associated with overall survival of pancreatic cancer
patients. This study tested whether genetic variability in
SLC22A3 associates with pancreatic cancer risk and prognosis.
Twenty four single nucleotide polymorphisms (SNPs) tagging the
SLC22A3 gene sequence and regulatory elements were selected for
analysis. Of these, 22 were successfully evaluated in the
discovery phase while six significant or suggestive variants
entered the validation phase, comprising a total study number
of 1,518 cases and 3,908 controls. In the discovery phase,
rs2504938, rs9364554, and rs2457571 SNPs were significantly
associated with pancreatic cancer risk.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
9
Citations
NaN
KQI